Abstract: Articles and methods related to the administration of biomolecules to subjects using metal-organic frameworks are generally described. In some embodiments, an article is described, the article comprising a substrate comprising an adhesive layer, a support layer disposed on at least a portion of the substrate, and an active material disposed on and/or in at least a portion of the support layer, wherein the active material comprises a composite comprising a metal-organic framework and a biomolecule. In certain embodiments, a method of treating a subject with a biomolecule is described, the method comprising administering an article to a subject.

Abstract: Pharmaceutical compositions may include chloroquine. More specifically, a pharmaceutical composition comprising chloroquine or pharmaceutically acceptable salt(s) thereof for use in the treatment or prevention of a viral lung infection, preferably caused by Betacoronavirus, including but not limited to 2019-nCoV (coronavirus), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV), wherein the pharmaceutical composition is administered by inhalation. An improved delivery into the lungs of a subject with minimum systemic exposure may be achieved.

Abstract: A liquid pharmaceutical formulation comprising etoposide toniribate; a polysorbate; and ethanol. A method of preparing an infusion solution comprising diluting said liquid pharmaceutical formulation. Said composition or solution for use in treating cancer in a patient in need thereof.

Abstract: The invention concerns a process for producing a stable, injectable solution containing noradrenaline, comprising the following steps: (a) dissolving noradrenaline and optionally one or more excipients in deoxygenated or degassed water, in order to produce a solution containing noradrenaline; (b) distributing the noradrenaline solution in an inert gas current into a container; (c) sterilizing the solution containing, before step (b) and/or after step (d); (d) hermetically sealing the container; (e) wherein the oxygen concentration in the solution containing noradrenaline is less than 300 ppbw immediately after sealing the container; and (f) wherein the oxygen concentration in the headspace immediately after sealing the container is at most 1.0 percent v/v. It also concerns a drug product obtainable in particular by the above process, and the use of a gas atmosphere comprising an oxygen concentration of less than 1.0 percent v/v, as a headspace in a container comprising a solution containing noradrenaline.

Abstract: The present invention relates to the field of hemodialysis and peritoneal dialysis, in particular to a fat emulsion dialysate, and preparation method and the use thereof. Provided in the present invention is a fat emulsion dialysate, comprising a long-chain fat emulsion oil, a medium-chain triglyceride, an anti-oxidant, sodium oleate, glycerin, phospholipid, and a solvent. Compared with traditional dialysis, the fat emulsion dialysate provided by the present invention has a better advantage for protein-bound toxin removal. In addition, the fat emulsion dialysate not only has a simple preparation method and a low cost, but also has good stability and safety, and remains stable at room temperature for 14 days without obvious precipitation. Thus, the fat emulsion dialysate can become a hemodialysis dialysate or peritoneal dialysate with broad application prospects, and has good industrialization prospects.

Abstract: A concentrate, characterized in that the concentrate contains a poorly soluble drug and a self-emulsifying carrier. The selfemulsifying carrier consists of the following substances: a composite emulsifier, which consists of phospholipid and nonphospholipid emulsifiers; an oil, which is medium chain triglyceride; and a co-emulsifier, which is anhydrous ethanol. The phospholipid is selected from soybean phospholipid, egg yolk lecithin, and a mixture thereof. The concentrate can be used to prepare an intravenous injection emulsion.

Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.

Abstract: The invention related to polynucleotides comprising an open reading frame of linked nucleosides encoding therapeutic proteins or variant therapeutic proteins, isoforms thereof, functional fragments thereof, and fusion proteins comprising therapeutic proteins. In some embodiments, the open reading frame is sequence-optimized. The invention also relates to methods of treating muscular dystrophies.

Abstract: A first inlet flow can be directed along an axial direction in a hydrocyclonic flow cell. The first inlet flow can include first constituent molecules. At a same time, one or more second inlet flows can be directed along a circumferential direction of the hydrocyclonic flow cell. Each second inlet flow can include a buffer solution. The first inlet flow can be subjected to flow focusing by a surrounding primary vortex formed by the one or more second inlet flows, so as to generate a flow comprising a plurality of nanoparticles at an outlet of the hydrocyclonic flow cell. Each nanoparticle can be formed by a respective plurality of the first constituent molecules.

Abstract: A method of producing a lipid-encapsulated RNA nanoparticle, comprising the steps a) flowing an aqueous solution comprising an RNA through a 1st tube having an inner diameter (ID) of between about 0.1? and 0.132?; b) flowing an ethanol solution comprising lipids through a 2nd tube having an ID of between about 0.005? and 0.02? at one third the flow rate of the aqueous solution through the 1st tube, wherein the lipids comprise a cationic lipid; and c) mixing the ethanol solution with the aqueous solution by flowing the ethanol solution and the aqueous solution into a mixing module consisting of the 2nd tube perpendicularly joined to the 1st tube; wherein the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about 10% to 75% ethanol v/v, and wherein the lipid-encapsulated RNA nanoparticles have a bilayer structure.

Abstract: In various embodiments, drug delivery vehicles that contain one or more metal-based therapeutic agents are provided. In certain embodiments, the drug delivery vehicle comprises: a silica nanoparticle comprising one or more cavities disposed within the nanoparticle and an outside surface where the one or more cavities are in fluid communication with the outside surface of the nanoparticle; a metal-based (e.g., platinum-based) chemotherapeutic drug disposed on the surface of the nanoparticle and/or within the one or more cavities of the nanoparticle where the drug comprises a cationic, metal-based drug; and a lipid bilayer disposed on the surface of the nanoparticle where the lipid bilayer fully encapsulates and seals the nanoparticle.

Abstract: Disclosed herein is a tablet for oral suspension comprising carglumic acid and its use.

Abstract: The present invention relates to a new formulation (a non-effervescent tablet) comprising Human Milk Oligosaccharides (HMOs), which dissolves or can be dispersed in water (or water based liquids) fast. The tablets are when dissolved can be consumed easily by a human.

Abstract: The present invention concerns a solid oral dosage form comprising albumin and at least one cannabinoid, wherein the oral dosage form is free of a gas generating agent (GGA) and wherein the oral dosage form is prepared using a compression force Q of below 1 ton.

Abstract: The invention relates to an extrusion additive manufacturing method for forming a drug delivery device. The method includes providing a first drug delivery material containing a first major excipient with a first melting range and a first melting peak. The method further includes extruding the first delivery material at an extrusion temperature that is within the melting range of the first major excipient.

Abstract: The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from mol % to 70 mol %; (iii) a ionizable, cationic lipid content of from 5 mol % to 50 mol %; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol % to 5 mol. Further provided is a lipid nanoparticle preparation comprising lipid nanoparticles having encapsulated mRNA and 20 to mol % of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticles exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. The lipid nanoparticles have an electron dense region and a nitrogen-to-phosphate charge ratio of between 4 and 15.

Abstract: The present invention provides a patch which prevents ketoprofen from forming a menthol ester, suppresses crystal precipitation, and yet shows excellent skin permeability. Specifically, the present invention provides a patch comprising ketoprofen, L-menthol, zinc oxide, and a fatty acid ester in a pasty preparation.

Abstract: Embodiments of the innovation relate to a dermal patch, comprising a substrate; a set of projections coupled to the substrate and configured to be at least partially insertable into skin, at least a portion of each projection of the set of projections comprising a biodegradable material; and a ghrelin blocker material encapsulated in the plurality of projections. The set of projections are coupled to the substrate via an adhesive that is configured to be dissolved within the skin after the patch is applied to the skin for a predetermined time, thus resulting in separation of the set of projections from the substrate. Once embedded in the skin, the protrusions can degrade and release the anti-ghrelin antibody encapsulated therein. The released anti-ghrelin antibody can find its way into the subject's circulatory system.

Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Abstract: Systems, compositions, and methods are disclosed for developing and delivering therapeutically effective 14,15-epoxyeicosatrienoic acid (14,15-EET) analogs, for example for pain management or treatment. Of particular interest are intermediate salts.

Abstract: The present invention relates to an application of 5-bromo-2-(?-hydroxyamyl) sodium benzoate salt (BZP) in treatment of ischemic cardiovascular and cerebral vascular diseases, in particular to a BZP compound for treatment of ischemic stroke and a treatment method, and more specifically, relates to a treatment solution for treating mild and moderate acute ischemic stroke by using the BZP and a pharmaceutical composition comprising the BZP.

Abstract: In one aspect, the present disclosure relates to a composition comprising a therapeutically effective amount a polyunsaturated fatty acid (PUFA). In another aspect, the present disclosure relates to a method of reducing a brain injury in a subject having an elevated risk of a traumatic brain injury or concussion, the method comprising: prophylactically administering to the subject a composition comprising a therapeutically effective amount of a PUFA. In yet another aspect, the present disclosure relates to sports drinks and dietary supplements comprising a PUFA. In some embodiments, the PUFA is an omega-6 PUFA such as omega-6 docosapentaenoic acid.

Abstract: An oil gel pharmaceutical composition, contains a liquid oil, a pharmaceutically acceptable gelator, a pharmaceutically acceptable stabilizer, and a pharmaceutically active component. The pharmaceutical composition is particularly suitable for a pharmaceutical preparation having anesthetic and analgesic activity, has good release duration and stability, can be used for injection and topical administration, has good patient tolerance and very few side effects.

Abstract: Disclosed herein are methods of treating a coronavirus infection by administration of ethyl mercury or thiol derivative thereof in an amount effective to treat the coronavirus infection.

Abstract: Self-assembling compounds for the formation of ion channels in biological membranes include monoacylated benzo(crown-ether) (MAcBCE) compounds and monoalkylated benzo(crown-ether) (MAkBCE) compounds. Methods of preparing the MAcBCE and MAkBCE compounds and methods of forming an ion channel in a biological membrane are also disclosed.

Abstract: A Sesquiterpene lactone compound, and a stereoisomer, isotopic marker, solvate and polymorph thereof, or a pharmaceutically acceptable salt thereof can be used in the preparation of drugs for alleviating radiotherapy-induced injuries. The Sesquiterpene lactone compound is applied to assist radiotherapy, can effectively alleviate the radiotherapy-induced injuries, achieves a protection effect on normal cell tissues of a human body.

Abstract: The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.

Abstract: A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferably over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.

Abstract: A method for treating age-related macular degeneration (AMD), either wet AMD or dry AMD. In the method, a therapeutic agent is administered to the patient. The therapeutic agent includes an antioxidant carbazole moiety fused to a nicotine analog. The patient is then monitored to determine the state of the age-related macular degeneration. The therapeutic agent may be administered orally, by injection, or by eye drops in preferred embodiments.

Abstract: A composition which comprises substance represented by Formula (I), [Meanings of the symbols that are included in the formula are given in the specification as definitions] a pharmaceutically acceptable carrier, and a dissolution aid. is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.

Abstract: Disclosed are novel carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a carboxyl or Carboxylic acid derivative containing compound.

Abstract: The present disclosure relates to a purified detomidine HCl pharmaceutical product and to methods of preparation, validation of pharmaceutically acceptable product and use thereof.

Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of 1-{2-fluoro-4-[5-(4-isobutylpheny 1)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.

Abstract: Co-agent combinations and/or formulations herein unexpectedly display significantly better antimicrobial activity (e.g., more efficacy and/or more potency) against anaerobic pathogens not previously considered targets. With three or more co-agents, selected from a group of a fosfomycin, a diaminopyridine, a sulfonamide, a beta lactam antibacterial, a bacterial beta-lactamase inhibitor, a bacterial fosfomycin-modifying enzyme, and a bacterial peptidoglycan synthesis inhibitor, the therapeutic potential of the three or more co-agents is expanded by targeting a broader spectrum of pathogens. Co-agents, by unexpected synergistic action in an anaerobic environment, are now active and efficacious against difficult to treat pathogenic anaerobes (including anaerobes that cannot utilize oxygen and/or reside in an anaerobic environment, some being inhibited by oxygen), as well as pathogens considered resistant or intolerant to at least one of the co-agents when used singly in an anaerobic environment.

Abstract: Pharmaceutical composition comprising rifaximin, a hydrogenated castor oil, and at least one additional solubilizing excipient for use in the treatment of sickle cell disease, vaso-occlusive crises or circulating ages neutrophils.

Abstract: Various aspects disclosed relate to an antibiotic adjuvant. The adjuvant includes the structure according to Formula I: In Formula I, R can be selected from: a substituted or unsubstituted (C1-C13)hydrocarbyl; the structure according to Formula II the structure according to Formula III the structure according to Formula IV and n is in a range of 1-10.

Abstract: Composition containing Nicotinamide and vitamin B6 are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be administered to an individual in need thereof for treating muscle injury, and/or promoting muscle repair, improving skeletal muscle regeneration, maintaining or increasing skeletal muscle function and/or skeletal muscle mass in an individual with muscle injury.

Abstract: Opicapone, or a pharmaceutically acceptable derivative thereof, in combination with levodopa, or a pharmaceutically acceptable derivative thereof, for use in treating the symptoms of Parkinson's disease in a patient suffering from unpredictable motor fluctuations.

Abstract: The present invention relates to a combination therapy of donepezil and sildenafil for the prevention, treatment or improvement of Alzheimer's disease or cognitive impairment. The combined administration of donepezil and sildenafil according to the present invention has a superior effect on improving Alzheimer's disease or cognitive impairment as compared to single administration of donepezil, which is able to be effectively used as a therapeutic therapy or a complex agent for Alzheimer's disease or cognitive impairment.

Abstract: The present invention provides a pharmaceutical composition for treating or preventing a disease caused in the vagina or perivaginal area by a pathogenic virus. The composition contains, as an active ingredient, a compound of an aniline derivative represented by the following formula (I): where W represents S or O, a pharmaceutically acceptable salt thereof, and a hydrate thereof. The pharmaceutical composition is in the form of a vaginal insert (e.g., a vaginal tablet, a vaginal capsule, or a vaginal suppository) containing a granular preparation, which includes core particles and a coating layer covering the core particles. The core particles contain the compound, needle-like and/or approximately column-like-shaped crystalline cellulose, a pharmaceutically acceptable approximately spherical shaped additive, and a nonionic surfactant. The granular preparation is characterized in that, in the core particles, voids are present between the crystalline cellulose and the additive.

Abstract: The present invention relates to pharmaceutical compositions of the c-Met inhibitor, Compound 1. The invention also relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase using the pharmaceutical composition and to processes for making the pharmaceutical compositions.

Abstract: A method for preventing, alleviating or treating disease in a patient comprising administering (orally or by injection, etc.) to the patient a prophylactic, alleviating or therapeutic amount of at least one of pyrroloquinoline quinone or a derivative thereof. PQQ is effective in preventing, alleviating or treating patient with primary dysmenorrhea, secondary dysmenorrhea and menstrual abnormalities accidentally.

Abstract: Methods for treating non-alcoholic steatohepatitis using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with one or more additional diseases selected from cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, obesity, and metabolic syndrome, wherein the metabolic syndrome may include, but is not limited to patient presentation of one or more of hypertension, hyperglycaemia, hyper-lipemia, insulin resistance (IR). In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced liver steatosis, reduced lobular inflammation, reduced hepatocellular ballooning, and reduced liver fibrosis.

Abstract: The present invention relates to an oral soft-gelatin capsule dosage form of Nintedanib and pharmaceutically acceptable salt thereof. The invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing marketed dosage form as well as nearest prior-arts. Moreover, the dissolution rate and stability of the patient compliant Nintedanib formulation, prepared as per the present invention, is proven higher when compared to prior art inventions. Furthermore, the present invention also provides an oily dispersion without using lecithin is prepared by a process which is relatively simple, easy to commercially manufacture, and functionally reproducible.

Abstract: Spray-dried metal-organic frameworks (MOFs) comprising therapeutic and/or diagnostic metal ions and therapeutic and/or diagnostic organic ligands are described. Both the metal ion and organic ligand can have activity related to the treatment and/or diagnosis of a pulmonary disease or disorder, such as tuberculosis, or another disease related to a pulmonary infection. The MOFs can be adminstered to subjects via inhalation (e.g., as aerosols). Methods of treating and diagnosing pulmonary diseases or disorders are also described.

Abstract: The present invention is directed to compositions for and methods for the treatment of presbyopia comprising from about 0.3% to about 2.0% w/v aceclidine and from about 0.07% to about 0.15% w/v brimonidine.

Abstract: A tyrosine kinase inhibitor for use in the treatment of COVID-19 and/or its associated symptoms. Also disclosed is a method of treating an individual infected with a coronavirus, wherein said method comprises the steps of: providing a tyrosine kinase inhibitor; and administering said tyrosine kinase inhibitor to said individual in a dosage amount sufficient to prevent/stabilize/reduce the risks and/or symptoms associated with a coronavirus infection.

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b)(i) a MEK inhibitor and/or (b)(ii) Bcl2 inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

Abstract: Provided is the present invention focusing on roles of IL-26 present in humans but not in mice by characterizing molecular mechanisms involved in interspecies differences in terms of efficacy of EGFR-TKI. The present inventors found that human cancers are exposed to IL-26 in a tumor microenvironment (TME), activating the EGFR-TKI bypass pathway, while suppression of IL-26 overcomes EGFR-TKI resistance in cancers. Furthermore, the present inventors identified EphA3 as a new functional receptor for IL-26 of TNBC. Therefore, the present invention provides a pharmaceutical composition for use in combination with an anticancer drug for treating cancer in a patient, the pharmaceutical composition containing a drug that reverses resistance to the anticancer drug by IL-26 as an active ingredient. Furthermore, the present invention provides a humanized anti-IL-26 antibody, and a therapeutic or preventive agent for refractory immune disorders or cancer using the antibody.